Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
The Sage Board of Directors will carefully review and evaluate Biogen’s proposal.
In November 2020, Biogen and Sage Therapeutics executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive…
